Thus, the process of IL-33-induced activation of memory-type ST2+CD4+ T cells may be a potential therapeutic target for steroid-resistant recurrent eosinophilic lung inflammation, including eosinophilic pneumonia. This evidence concerns the gene IL33 and eosinophilic pneumonia.